NCT07112872: A Study to Compare Different Doses of Tifeglipron (RO7795081) With Placebo or Semaglutide in People With Type 2 Diabetes
- State
- Under way
- Phase
- Phase 2
- People
- 330 planned
- Started
- 19 Aug 2025
- Primary completion
- 5 Feb 2028
- Arms
- Part A, Arm 3: Tifeglipron Dosing Regimen 1, Part A, Arm 4: Tifeglipron Dosing Regimen 2, Part A, Arm 5: Tifeglipron Dosing Regimen 3, Part A, Arm 6: Tifeglipron Dosing Regimen 4, Part A, Arm 7: Tifeglipron Dosing Regimen 5, Part A, Arm 8: Tifeglipron Dosing Regimen 6, Part A, Arm 9: Tifeglipron Dosing Regimen 7, Part B, Arm 2: Tifeglipron Dosing Regimen A, Part B, Arm 3: Tifeglipron Dosing Regimen B
- Results
- None posted
- 8 Aug 2025: Trial registered
- 19 Aug 2025: Trial started